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Abstract 
Background: Romifidine, an α-2 adrenoceptor agonist, is a widely-used sedative in equine medicine. Besides the 
desired sedative and analgesic actions, α-2 adrenoceptor agonists have side effects like alterations of plasma con-
centrations of glucose and certain stress-related hormones and metabolites in various species. Vatinoxan (previously 
known as MK-467), in turn, is an antagonist of α-2 adrenoceptors. Because vatinoxan does not cross the blood brain 
barrier in significant amounts, it has only minor effect on sedation induced by α-2 adrenoceptor agonists. Previously, 
vatinoxan is shown to prevent the hyperglycaemia, increase of plasma lactate concentration and the decrease of 
insulin and non-esterified free fatty acids (FFAs) caused by α-2 adrenoceptor agonists in different species. The aim 
of our study was to investigate the effects of intravenous romifidine and vatinoxan, alone and combined, on plasma 
concentrations of glucose and some stress-related hormones and metabolites in horses.
Results: Plasma glucose concentration differed between all intravenous treatments: romifidine (80 μg/kg; ROM), 
vatinoxan (200 μg/kg; V) and the combination of these (ROM + V). Glucose concentration was the highest after ROM 
and the lowest after V. Serum FFA concentration was higher after V than after ROM or ROM + V. The baseline serum 
concentration of insulin varied widely between the individual horses. No differences were detected in serum insulin, 
cortisol or plasma adrenocorticotropic hormone (ACTH) concentrations between the treatments. Plasma lactate, 
serum triglyceride or blood sodium and chloride concentrations did not differ from baseline or between the treat-
ments. Compared with baseline, plasma glucose concentration increased after ROM and ROM + V, serum cortisol, 
FFA and base excess increased after all treatments and plasma ACTH concentration increased after V. Serum insulin 
concentration decreased after V and blood potassium decreased after all treatments.
Conclusions: Romifidine induced hyperglycaemia, which vatinoxan partially prevented despite of the variations in 
baseline levels of serum insulin. The effects of romifidine and vatinoxan on the insulin concentration in horses need 
further investigation.
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Background
Romifidine is an α-2 adrenoceptor agonist which is com-
monly used to induce sedation and analgesia in horses. 
In addition to their sedative and analgesic effects, α-2 
adrenoceptor agonists have a marked effect on plasma 
concentrations of glucose and some stress-related hor-
mones and metabolites; romifidine, xylazine and detomi-
dine increase plasma glucose concentrations by inhibiting 
insulin release from pancreatic β-cells in horses [1, 2], 
ponies [3] and mice [4]. Detomidine is also reported to 
increase base excess (BE), indicating metabolic alkalosis 
[5] and to decrease the plasma concentration of free fatty 
acids (FFAs, or non-esterified free fatty acids) [3] and cor-
tisol [3, 6] in horses. In contrast, in one study detomidine 
had no effect on plasma cortisol concentration [7]. Fur-
thermore, plasma cortisol and adrenocorticotropic hor-
mone (ACTH) concentrations decreased in horses after 
administration of clonidine, another α-2 adrenoceptor 
agonist [8]. The plasma concentration of potassium  (K+) 
is reported to be unaffected by α-2 adrenoceptor agonists 
in horses [9]. In theory, decreased insulin concentration 
could result in hyperkalemia through diminished cellular 
 K+ influx, as shown in dogs and humans [10].
The effects of α-2 adrenoceptor agonists on energy 
metabolism, stress-related hormones and metabolites 
can be attenuated by α-2 adrenoceptor antagonists. Ati-
pamezole and yohimbine antagonized medetomidine-
induced hyperglycaemia, hypoinsulinaemia and decrease 
in FFA concentration in dogs; the effect of atipamezole 
was reported to be dose-dependent [11]. Atipamezole 
also attenuated hyperglycaemia and decrease in FFA 
concentration in cats [12], and hyperglycaemia in cat-
tle [13] and goats [14]. Contradictory results have also 
been reported; atipamezole did not affect hyperglycae-
mia [15] while the α-2 adrenoceptor antagonist tolazoline 
caused a rapid increase in plasma glucose concentration 
in horses treated with detomidine [3]. In addition, tolazo-
line attenuated the detomidine-induced decrease in FFA 
concentration transiently [3]. All of these α-2 adrenocep-
tor antagonists reverse, at least partly, both the sedative 
and analgesic effects induced by α-2 adrenoceptor ago-
nist [3, 16–18], a feature which is often undesired.
Vatinoxan, previously known as MK-467 and 
L-659,066, is an α-2 adrenoceptor antagonist which 
poorly penetrates the blood brain barrier. Therefore, it 
targets mainly peripherally located α-2 adrenoceptors 
[19]. Vatinoxan prevented the hyperglycaemic effect of 
clonidine in humans [20] and mice [21]. In dogs, vati-
noxan prevented the slight increase of plasma lactate 
and glucose concentrations and the decrease of insulin 
and FFA induced by the α-2 adrenoceptor agonist dex-
medetomidine [22]. Vatinoxan, in addition, enhanced 
insulin responses to glucose in mice [21] and to exercise 
in humans [23]; although, in another study vatinoxan 
showed no effect on plasma glucose, insulin or insulin 
response to glucose in humans [24]. The effect of vati-
noxan on quality of sedation induced by detomidine or 
romifidine in horses [25, 26] and dexmedetomidine in 
dogs [27–29] is only minor because it acts predominantly 
on peripheral α-2 adrenoceptors.
The aim of this study was to explore whether the intra-
venous (IV) administration of romifidine or vatinoxan 
induces changes in plasma concentrations of glucose or 
some metabolites and stress-related hormones in horses, 
and whether vatinoxan is able to antagonise the possible 
effects of romifidine when these agents are administered 
simultaneously. To the best of our knowledge, there are 
no previous reports of the effects of romifidine in com-
bination with vatinoxan, on plasma concentrations of 
glucose or stress-related hormones and metabolites in 
horses or any other species.
Methods
Seven Finnhorse mares aged 15 ± 5  years (mean ± SD) 
and with a body weight (BW) of 586 ± 44 kg were used in 
this study. The horses were considered healthy based on 
clinical examination (inspection of mucous membranes, 
measuring of capillary refill time and body temperature 
and auscultation of heart, lungs and intestinal sounds). 
Screening blood samples were not taken before the trials. 
The routine diet of these horses consisted of hay, silage 
and concentrates. On the day of the trials, the horses 
were fed normal hay and silage, but not concentrates, and 
had free access to water.
Baseline blood samples were drawn in the stables via 
puncture of jugular vein, after which the horses were 
taken to examination room and restrained in stocks. Two 
14G, 80 mm intravenous catheters (Intraflon 2, Labora-
toires Pharmaceutiques Vygon Uk Ltd., UK) were placed 
in the right jugular vein at least 15 cm apart under local 
infiltration of the skin with lidocaine (Lidocain 20  mg/
mL, Orion Pharma, Espoo, Finland). An 18G, 70 cm cen-
tral venous catheter (Cavafix Certo, B. Braun Melsungen 
AG, Melsungen, Germany) was placed in the left jugular 
vein and a 20G, 45  mm catheter (BD Arterial cannula, 
Becton–Dickinson India Pvt., India) was placed in the 
transverse facial artery under local skin infiltration with 
lidocaine. All catheters were sutured to the adjacent skin, 
except the caudal jugular catheter, which was used for 
the administration of medications and was immediately 
removed after injection. The remaining cranial jugular 
catheter was used for blood sampling. The arterial cath-
eter was used for sampling for arterial blood gas analysis 
and for monitoring arterial blood pressure, and the cen-
tral venous catheter for monitoring central venous blood 
pressure; these results are a subject of a separate paper 
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[26]. The horses used in the study were research horses 
that were accustomed to minor procedures like IV punc-
tures. Some of the horses mildly resisted their placement 
into the stocks and one horse got agitated by standing in 
the stocks for a long time without sedation. All the horses 
tolerated instrumentation without marked resistance. To 
obtain full immobility during arterial catheter placement, 
a twitch was used in all of the horses. All the catheters 
were removed at the end of the trial and replaced at the 
day of next trial.
Each horse was treated three times by means of a 
blinded cross-over Latin square design with a minimum 
washout period of 6  days. Venous blood samples were 
collected into EDTA, fluoride-oxalate and serum tubes in 
the stable (baseline) before each horse was taken to the 
examination room for instrumentation, administration of 
drugs and monitoring. After instrumentation, the horses 
were let to settle down for 5 min before administration of 
the medications. The horses received the following medi-
cations intravenously:
1. Romifidine hydrochloride (HCl) (80 μg/kg BW, Sedi-
vet, Boehringer Ingelheim Vetmedica GmbH, Ingelheim, 
Germany; ROM). 2. Romifidine HCl (80 μg/kg BW) and 
Vatinoxan HCl (200  μg/kg BW, Vetcare Ltd, Salo, Fin-
land; ROM + V). 3. Vatinoxan HCl (200 μg/kg BW; V).
Vatinoxan HCl was supplied as a powder. For each 
treatment, the drugs were diluted in saline (Natrium-
klorid, B. Braun Melsungen AG, Germany) in a single 
syringe to a total volume of 20  mL, and were admin-
istered IV as a bolus injection over 15  s at T0. Venous 
blood samples were taken 15, 30, 60, 90 and 120  min 
(T15–T120, respectively) after drug administration. 
EDTA and fluoride-oxalate tubes were placed in ice water 
immediately after blood sampling and centrifuged within 
10  min to separate the plasma. Fluoride-oxalate plasma 
for analysis of lactate and glucose was refrigerated until 
analysis (maximum of 48  h). EDTA plasma was frozen 
at − 20  °C until ACTH analysis. Tubes for serum sam-
ples were kept at room temperature until centrifugation, 
which was performed on the same day. Serum was frozen 
at − 20  °C to await cortisol, FFA, triglyceride and insu-
lin analyses. The laboratories analysing the blood sam-
ples were unaware of the treatments administered to the 
horses.
Lactate was analysed with enzymatic lactate oxidase 
(Konelab™ Lactate PAP, Thermo Fisher Scientific Ltd, 
Vantaa, Finland), glucose with the photometric glu-
cose hexokinase 2-reagent method (Konelab™ Glucose 
HK) and triglycerides with the enzymatic colorimet-
ric method (Konelab™ Trigycerides; Konelab 30i Clini-
cal Chemistry Analyzer). The enzymatic colorimetric 
method was used for the determination of FFAs (NEFA-
C, Wako Chemicals GmbH, Neuss, Germany; KONE Pro 
Selective Chemistry Analyzer, Thermo Fisher Scientific 
Ltd). ACTH was analysed with a solid-phase, two-site 
sequential chemiluminescent immunometric assay and 
insulin with a solid-phase, enzyme-labelled chemilumi-
nescent immunometric assay (Immulite 2000, Siemens 
Healthcare Diagnostics Products GmbH, Marburg, Ger-
many). Plasma cortisol concentration was analysed by 
RIA (Spectria cortisol RIA kit, Orion Diagnostica Ltd, 
Espoo, Finland), and samples were run as duplicates.
Venous blood gas samples (PICO50 blood gas syringes; 
Radiometer Medical ApS, Denmark) were taken after 
instrumentation (baseline) and at T5, T15, T30 and T60 
after drug administration for measurement of potassium 
 (K+), sodium  (Na+), chloride  (Cl−) and base excess (BE) 
(IDEXX VetSta; ME, USA).
The normality assumptions were evaluated with Shap-
iro–Wilk tests. Friedman’s two-way analysis of variance 
for related samples was used to compare serum insu-
lin concentrations to baseline within each treatment. 
Kruskall–Wallis test was used for comparisons of serum 
insulin concentrations between the treatments. Concen-
trations of all other variables were compared between the 
treatments with repeated measures analysis of variance 
(rmANOVA) and pairwise comparisons within each time 
point were conducted with Student’s t test. All signifi-
cance values were adjusted by Bonferroni correction for 
multiple tests. Significance was set at P < 0.05.
Results
Romifidine induced sedation in all of the horses and vati-
noxan did not significantly affect the quality of sedation. 
Vatinoxan administered alone caused mild abdominal 
discomfort and watery faeces in some of the horses, but 
otherwise it was well tolerated. When romifidine and 
vatinoxan were administered simultaneously, many of the 
peripheral cardiovascular and intestinal side-effects of 
romifidine were alleviated [26].
Plasma glucose concentration showed significant dif-
ferences between all treatments. The concentration was 
the highest after ROM and the lowest after V. Compared 
to baseline, ROM and ROM + V, but not V, significantly 
increased plasma glucose concentration (Fig. 1).
Serum insulin concentrations of five horses were within 
the laboratory reference range (0–19  µU/mL, Animal 
Laboratory Vetlab, Tampere, Finland) at all time-points. 
The remaining two horses had their values above the ref-
erence range at several measuring points; concentrations 
varied from below detection level (2  µU/mL)–82.9  µU/
mL. No significant differences in insulin concentration 
were detected between treatments, but the inter-individ-
ual variation was high. Insulin concentration significantly 
decreased from baseline after V (Table 1).
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Serum FFA concentration was higher after V than 
ROM or ROM + V. Serum FFA concentrations increased 
from baseline after all treatments (Fig. 2).
Baseline plasma ACTH concentrations were within the 
reference range (< 35 pg/mL, Animal Laboratory Vetlab) 
in all but one horse, which had a higher concentration 
before ROM + V. After the treatments, the values varied 
from 5.82 to 74.9 pg/mL, except for one measurement in 
one horse of 185 pg/mL at T120 after ROM. This reading 
was confirmed by measuring in duplicate. Plasma ACTH 
concentrations, relative to baseline, increased after MK 
at T15 and T30, but significant differences were not 
detected between treatments. Plasma lactate and serum 
triglyceride concentrations did not differ significantly 
from baseline or between treatments. Serum cortisol 
concentrations increased from baseline after all treat-
ments, but no significant differences emerged between 
treatments (Table 2).
Base excess showed an increasing trend after all treat-
ments and there was a significant difference between 
baseline and T60 after ROM and V, but no significant 
differences were detected between the treatments. Potas-
sium, in contrast, decreased after all the treatments and 
the concentrations were significantly lower than base-
line at T15 after ROM and ROM + V, and at T60 after 
ROM + V and V. There was also a significant difference 
in  K+ concentrations between ROM + V and V at T15 
(Table  2). Sodium and  Cl− concentration were stable 
trough the monitoring period (data not shown).
Discussion
As far as we are aware, this is the first study reporting 
the effects of romifidine administered in combination 
with vatinoxan, on plasma concentrations of glucose or 
hormones and metabolites in any animal species. In this 
study, romifidine induced hyperglycaemia in horses and 
the plasma glucose concentration remained high until 
the end of the monitoring period of 120 min. This indi-
cates that the effect of romifidine on plasma glucose 
concentration is long lasting and that plasma glucose 
concentration may, indeed, have peaked after the last 
time point of this study. These findings are in agree-
ment with previous studies from horses treated with 
romifidine [1], detomidine [3, 18] and dogs treated with 
xylazine, medetomidine and dexmedetomidine [22, 30]. 
In contrast, Raekallio and co-workers [31] reported a 
decrease in plasma glucose concentration in dogs after 
dexmedetomidine administration, but they noted that 
their monitoring period of 90 min might have been too 
short to detect possible hyperglycaemia. It is noticeable 
that the sedative effect of romifidine was already ceased 
at the point of highest plasma glucose concentration 
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Fig. 1 Mean plasma glucose concentration of seven horses. The 
horses received romifidine (ROM, 80 μg/kg IV), ROM with vatinoxan 
(ROM + V, 80 μg/kg + 200 μg/kg IV) and vatinoxan (V, 200 μg/kg 
IV) at T0. Error bars indicate the standard deviation. Plasma glucose 
concentrations were significantly different (P < 0.05) from baseline 
at T60 and T120 after ROM and at T30, T60 and T120 after ROM + V. 
Significant difference (P < 0.05) between * ROM and ROM + V, 
†ROM + V and V and ‡ROM and V
Table 1 Serum insulin concentrations
Medians (and highest concentrations) of serum insulin concentration of seven 
horses (µIU/mL). The horses received romifidine (ROM, 80 μg/kg IV), ROM with 
vatinoxan (ROM + V, 80 μg/kg + 200 μg/kg IV) and MK-467 (V, 200 μg/kg IV) at 
T0. The lowest concentration after all treatments at all time points was below the 
detection limit (< 2 µIU/mL)
* Significantly different (P < 0.05) from baseline (T0), no significant differences 
detected between treatments
Baseline T15 T30 T60 T120
ROM 6.0 (83) < 2.0 (49) < 2.0 (45) < 2.0 (32) < 2.0 (42)
ROM + V 4.8 (58) < 2.0 (45) < 2.0 (62) < 2.0 (39) < 2.0 (59)
V 7.8 (80) 3.2 (74) < 2.0 (47)* 4.3 (58) < 2.0 (43)*
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Fig. 2 Mean serum FFA concentration of seven horses. The horses 
received romifidine (ROM, 80 μg/kg IV), ROM with vatinoxan 
(ROM + V, 80 μg/kg + 200 μg/kg IV) and vatinoxan (V, 200 μg/
kg IV) at T0. Error bars indicate the standard deviation. Serum FFA 
concentrations were significantly different (P < 0.05) from baseline at 
T30 after ROM, at T15 and T30 after ROM + V and at T30 and T60 after 
V. Significant difference (P < 0.05) between †ROM + V and V and ‡ROM 
and V
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[26], which means that its effect on energy metabolism is 
longer lasting than the sedative action.
Plasma glucose concentration also increased after 
ROM + V, although to a lesser extent than after ROM. 
This suggests that V partially prevented romifidine-
induced hyperglycaemia. Prevention of the haemody-
namic effects of dexmedetomidine by vatinoxan in dogs is 
reported to be dose-dependent [32]. This could also apply 
to the effects of vatinoxan on alterations in plasma hor-
mone and metabolite concentrations caused by alpha-2 
adrenoceptor agonists. On that basis, we assumed that 
the dose of 200  µg/kg used in our study might have 
been inadequate for complete prevention of romifidine-
induced hyperglycaemia. In dogs, for example, vatinoxan 
completely antagonized dexmedetomidine (10  µg/kg) 
induced hyperglycaemia at the dose of 500  µg/kg [22]. 
Of the other α-2 adrenoceptor antagonists, antagonism 
of medetomidine induced hyperglycaemia and hypo-
insulinaemia in dogs by atipamezole is also reported to 
be dose-dependent [11]. In humans, vatinoxan partially 
inhibited both the clonidine-induced increase of plasma 
glucose and reduction of plasma insulin concentra-
tion. These authors speculated that glucose homeosta-
sis could be only partially regulated by peripheral α-2 
adrenoceptors, which would also explain the incomplete-
ness of inhibition [33].
In our study, vatinoxan, when administered alone, 
did not significantly affect plasma glucose concentra-
tion. This finding is in agreement with previous reports 
in which vatinoxan did not change plasma glucose or 
insulin concentrations in normoglycaemic fasted mice 
[21] or humans [33, 34]. In contrast, vatinoxan increased 
insulin and decreased plasma glucose concentration in 
hyperglycaemic mice [21]. However, despite no signifi-
cant difference in plasma glucose concentration, vati-
noxan decreased serum insulin concentration in the 
present study. This might relate to the balance between 
inhibition of α-2 adrenoceptors in pancreatic β-cells 
and increased sympathoadrenal output and concentra-
tion of catecholamines due to stress caused by restraint 
of non-sedated horses in stocks. The ability of vatinoxan 
to decrease serum insulin in horses could be a useful fea-
ture in horses suffering from equine metabolic syndrome 
(EMS), as hyperinsulinaemia is known to predispose 
these horses to laminitis [35].
Alpha-2 adrenoceptor agonist-related hyperglycaemia 
is known to result from a reduction of insulin release 
by a direct action of the α-2 adrenoceptor agonist on 
Table 2 Plasma ACTH and lactate, serum triglyceride, cortisol and blood  K+,  Na+ and BE concentrations
Means (± SD) of plasma ACTH (pg/mL), plasma lactate (mmol/L), serum triglyceride (mmol/L), serum cortisol (nmol/mL) and venous blood  K+and BE (mmol/L) 
concentrations of seven horses. The horses received romifidine (ROM, 80 μg/kg IV), ROM with vatinoxan (ROM + V, 80 μg/kg + 200 μg/kg IV) and vatinoxan (V, 200 μg/
kg IV) at T0
* Significantly different (P < 0.05) from baseline (T0)
$  Significant difference between treatments
Analyte Treatment Baseline T15 T30 T60 T120
ACTH ROM 16.8 (± 3.83) 32.3 (± 22.4) 25.0 (± 12.5) 18.7 (± 7.66) 44.7 (± 62.4)
ROM + V 19.4 (± 11.1) 28.5 (± 12.4) 21.6 (± 8.39) 21.4 (± 13.2) 19.1 (± 11.1)
V 17.3 (± 6.53) 32.2* (± 6.66) 29.0* (± 5.71) 23.0 (± 5.68) 16.1 (± 5.68)
Lactate ROM 0.60 (± 0.30) 0.61 (± 0.17) 0.63 (± 0.24) 0.49 (± 0.11) 0.41 (± 0.24)
ROM + V 0.58 (± 0.29) 0.69 (± 0.24) 0.70 (± 0.27) 0.71 (± 0.24) 0.56 (± 0.17)
V 0.50 (± 0.59) 0.55 (± 0.35) 0.55 (± 0.33) 0.61 (± 0.30) 0.70 (± 0.35)
Triglycerides ROM 0.30 (± 0.10) 0.36 (± 0.13) 0.37 (± 0.13) 0.36 (± 0.13) 0.27 (± 0.07)
ROM + V 0.27 (± 0.03) 0.30 (± 0.06) 0.30 (± 0.09) 0.29 (± 0.12) 0.24 (± 0.12)
V 0.28 (± 0.08) 0.32 (± 0.09) 0.33 (± 0.11) 0.30 (± 0.10) 0.23 (± 0.11)
Cortisol ROM 59.0 (± 13.9) 120* (± 34.7) 106 (± 37.6) 86.6 (± 35.4) 113 (± 51.7)
ROM + V 51.9 (± 16.1) 107* (± 24.7) 84.1 (± 23.1) 76.5 (± 29.0) 66.3 (± 26.5)
V 61.2 (± 14.7) 131* (± 34.2) 120* (± 30.4) 102 (± 23.5) 79.4 (± 32.7)
Analyte Treatment Baseline T5 T15 T30 T60
BE ROM 4.00 (± 0.54) 4.04 (± 0.95) 4.47 (± 0.47) 4.76 (± 0.79) 5.74* (± 0.88)
ROM + V 4.46 (± 1.43) 4.19 (± 1.32) 4.31 (± 1.55) 4.84 (± 1.30) 5.41 (± 1.06)
V 3.86 (± 0.78) 3.63 (± 0.87) 3.96 (± 0.96) 4.19 (± 0.66) 5.24* (± 0.57)
K+ ROM 4.30 (± 0.26) 4.16 (± 0.28) 4.09* (± 0.28) 4.16 (± 0.30) 4.17 (± 0.27)
ROM + V 4.20 (± 0.29) 4.11 (± 0.40) 3.87*,$ (± 0.28) 3.91 (± 0.25) 3.84* (± 0.27)
V 4.44 (± 0.36) 4.39 (± 0.28) 4.30$ (± 0.31) 4.21 (± 0.36) 3.94* (± 0.31)
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pancreatic β-cells [4]. However, in our study this asso-
ciation between hyperglycaemia and hypoinsulinaemia 
could not be demonstrated, because in the majority of 
the samples the serum insulin concentration was below 
the detection limit of the analysing method. In individ-
ual horses, romifidine seemed to cause an increase in 
plasma glucose concentration, while the insulin concen-
tration stayed below the detection limit. This could sug-
gest that even a slight decrease of insulin concentration, 
which was not detectable in the analysis, may result in 
hyperglycaemia or there could have been other factors 
affecting the increase of glucose concentration. Find-
ings in previous studies [11, 30, 36] suggest that the α-2-
mediated decrease in plasma insulin concentration might 
not be the only factor affecting blood glucose concentra-
tion in animals treated with α-2 adrenoceptor agonists. 
We also suggest that some of the effects of romifidine on 
glucose concentration might have been other than α-2 
adrenoceptor activation in pancreas, such as hepatic gly-
cogenolysis induced by α-2-adrenergic agents and gluco-
neogenesis mediated by α-1 adrenoceptors, as romifidine 
is stated to be partial α-2 adrenoceptor agonist [37] or to 
have α-2:α-1 selectivity of 340:1 [38]. Some of the effects 
might also be mediated by central imidazoline receptors, 
as romifidine is an imidazoline derivative.
Serum cortisol concentration increased rather quickly 
after each treatment, after which it slowly decreased 
again. Plasma ACTH concentrations showed a similar 
trend, although the increase was significant only after 
V. These increases are probably due to stress induced by 
instrumentation and confinement to stocks. Instrumen-
tation procedure was the same before every trial and we 
assume that the bias caused by stress from instrumenta-
tion would be similar throughout the experiment. Short 
term increases in serum cortisol concentration could be 
of clinical importance in EMS or pituitary pars inter-
media dysfunction (PPID) patients because they are 
reported to enhance vasoconstriction in laminar veins 
in vitro, creating a possible risk factor for laminitis [39]. 
There are conflicting reports on the effects of α-2 adreno-
ceptor agonists on cortisol concentration in various spe-
cies. Plasma cortisol concentration is reported to either 
decrease or to remain constant in horses [3, 6, 7], to 
remain constant in various other species such as dogs 
[11, 22, 30] and calves [13] or to increase in dairy cows, 
sheep and goats [13, 14]. Other factors, such as differ-
ences between species, differences in baseline cortisol 
concentrations and stress related to the environment or 
sampling procedures, likely affected cortisol concentra-
tions in these studies. Cortisol concentration is known 
to fluctuate during the day in horses; it is highest from 
morning until early afternoon (8 a.m.–14 p.m.) and low-
est before midnight, around 10–12 p.m. [40–42]. To 
avoid the effect of diurnal variation in our results, all 
three treatments were conducted at approximately the 
same time of the day for each horse.
In the present study, we detected an increase in serum 
concentrations of FFA after each treatment. The concen-
tration of FFA was significantly higher after V than after 
ROM or ROM + V, which, in turn, did not differ sig-
nificantly from each other. This was indicative of stress 
caused by instrumentation, which most likely increased 
catecholamine plasma concentrations. This was mani-
fested as increased FFA concentration. Alpha-2 adreno-
ceptor agonists are previously reported to decrease 
serum FFA in horses [3] and dogs [22, 30]. In our study, 
romifidine-induced sedation probably affected serum 
FFA concentration only partially because the stress 
increasing the FFA concentrations was induced before 
the horses received the medications. The stress caused 
by procedures may also overcome the decreasing actions 
of α-2 adrenoceptor agonists on serum FFA, which is 
reported in horses undergoing standing laparoscopy [43]. 
The greater increase in serum FFA after V could also 
result partly from a direct effect of vatinoxan on lipolysis 
as vatinoxan is reported to increase the plasma concen-
tration of FFA [23] and, furthermore, α-2 adrenoceptor 
antagonists potentiate the lipolytic action of adrenaline in 
humans [44]. In dogs, plasma FFA concentration showed 
a biphasic response after the combined administration 
of vatinoxan with dexmedetomidine. Initially, a similar 
decrease was noticed after both medications, but later 
the concentration increased significantly more after the 
combined administration [22]. The temporal discrepancy 
was speculated to result from the balance between cat-
echolamine and insulin concentrations since both affect 
the activity of hormone-sensitive lipase, which is the 
main regulator of lipolysis [45].
As all lactate concentrations were within the refer-
ence range (< 1.5  mmol/L, Laboratory Ellab, Ypäjä, Fin-
land) and the concentrations did not differ significantly 
from baseline values, which indicates that there was no 
evidence of tissue hypoxia or lactic acidosis after any of 
the treatments. In fact, as the BE increased after all treat-
ments, the metabolic state of the horses changed towards 
metabolic alkalosis during the experiment. This obser-
vation is in agreement with previous findings of Raekal-
lio and co-workers [5]. Possible reasons for the change 
toward alkalosis after romifidine administration in the 
present study are altered renal function and compensa-
tory response to respiratory acidosis due to decreased 
respiratory rate and increased arterial carbon dioxide 
tension [26]. As there was significant increase in BE dur-
ing this relatively short sampling period, further investi-
gation is needed to examine if the metabolic alkalosis will 
be clinically relevant for example after long infusions of 
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α-2 adrenoceptor agonists for veterinary standing proce-
dures that have become more common in recent years.
The blood  K+ concentrations of the horses in our study 
decreased although the change was not clinically rel-
evant. The regulation of blood potassium concentration 
is complex and involves, for example, aldosterone, insu-
lin, sympathomimetics, and is regulated by the acid–base 
balance and renal function. Because of the high concen-
tration difference between intracellular and extracellular 
potassium content, alterations in blood potassium con-
centrations are often a result of redistribution of potas-
sium between these compartments [46]. Renal excretion 
of potassium is increased during metabolic alkalosis. 
Furthermore, both urine production and renal excretion 
of electrolytes are increased by alpha-2 adrenoceptor 
agonists [9], and one possible explanation of decreased 
potassium in the present study is increased loss to urine. 
Considering the complexity of potassium homeostasis, 
the effects of romifidine and vatinoxan on blood potas-
sium need further investigation.
Conclusions
Romifidine induced hyperglycaemia in horses is simi-
lar to other α-2 adrenoceptor agonists, but its effects on 
serum insulin warrant further investigations. Vatinoxan 
was able to alleviate the romifidine induced hypergly-
caemia despite of the wide variation in baseline insulin 
concentrations. Further research is needed to evaluate 
the metabolic changes under stressful situations, such as 
veterinary procedures or in compromised patients (e.g. 
critically ill foals and adult horses with underlying disease 
processes such as PPID and EMS). In these patients, the 
metabolic and hormonal changes induced by α-2 adreno-
ceptor agonists may be of clinical importance, espe-
cially because they last longer than the sedative action of 
romifidine.
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